威猛和异环磷酰胺两种方案治疗晚期非小细胞肺癌的对比研究  

Comparative study of VM_(26)and IFO regimen in advanced stage non-small-cell lung cancer

作　　者：王导新[1] 蒋幼凡[1] 杜先智[1] 薛亚梅[1] 

机构地区：[1]重庆医科大学附属第二临床学院肺科,重庆400010

出　　处：《重庆医科大学学报》2001年第3期335-336,共2页Journal of Chongqing Medical University

摘　　要：目的：为了研究威猛＋表阿霉素＋卡铂方案与异环磷酰胺＋表阿霉素＋顺铂方案分别治疗两组晚期非小细胞肺癌（ＮＳＣＬＣ）的临床疗效和毒副反应。方法：５８例晚期非小细胞肺癌（ＮＳＣＬＣ）作为研究对象，随机分为两组，威猛联合方案组２７例，异环磷酰胺联合方案组３１例。均有病理学依据。每４周为一周期，两个周期后方可评价疗效。结果：威猛联合方案组有效率为３７．０％（１０／２７），中位生存期为８．３个月；异环磷酰胺联合方案组有效率为３８．７％（１２／３１），中位生存期为８．１个月。　两指标均无统计学差异（Ｐ＞０．０５）。毒性反应主要是骨髓抑制，脱发及恶心，呕吐。结论：两种方案临床疗效接近，毒性反应相似，耐受性较好。Objective: To compare the effectiveness and toxicity in treatment of non-small-cell lung cancer with VM26+EPI+CBP regimen and IFO +EPI+DDD regimen.Methods： 58 patients with advanced stage NSCLC were randomizer into VM26group and IFO group.27 patients were treated wit h VM26regimen,31 patients were treated with IFO regimen.Results： The response rate were 37.0%(10/27)for VM26regimen and 38.7%(12/3 1)for IFO regimen,median survival time was 8.3 months for VM26regimen and 8.1 months for IFO regimen.There was no significant difference(P＞0.05) for bothof between two groups. Conclusion：Similar response rate was se en in both groups.The toxicity of myelosuppression of IFO group was a little bit more serious than the toxicity of VM26groups.

关 键 词：非小细胞肺癌 联合化疗 威猛 异环磷酰胺 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]